Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 27 entries
Sorted by: Best Match Show Resources per page
Pan-Cancer Analysis of Mutation Hotspots in Protein Domains.

Cell systems

Miller ML, Reznik E, Gauthier NP, Aksoy BA, Korkut A, Gao J, Ciriello G, Schultz N, Sander C.
PMID: 27135912
Cell Syst. 2015 Sep 23;1(3):197-209. doi: 10.1016/j.cels.2015.08.014. Epub 2015 Sep 23.

In cancer genomics, recurrence of mutations in independent tumor samples is a strong indicator of functional impact. However, rare functional mutations can escape detection by recurrence analysis owing to lack of statistical power. We enhance statistical power by extending...

Cite
Miller ML, Reznik E, Gauthier NP, et al. Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. Cell Syst. 2015;1(3):197-209doi: 10.1016/j.cels.2015.08.014.
Miller, M. L., Reznik, E., Gauthier, N. P., Aksoy, B. A., Korkut, A., Gao, J., Ciriello, G., Schultz, N., & Sander, C. (2015). Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. Cell systems, 1(3), 197-209. https://doi.org/10.1016/j.cels.2015.08.014
Miller, Martin L, et al. "Pan-Cancer Analysis of Mutation Hotspots in Protein Domains." Cell systems vol. 1,3 (2015): 197-209. doi: https://doi.org/10.1016/j.cels.2015.08.014
Miller ML, Reznik E, Gauthier NP, Aksoy BA, Korkut A, Gao J, Ciriello G, Schultz N, Sander C. Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. Cell Syst. 2015 Sep 23;1(3):197-209. doi: 10.1016/j.cels.2015.08.014. Epub 2015 Sep 23. PMID: 27135912; PMCID: PMC4982675.
Copy Download .nbib Format: NLM
Value of p53 protein expression and its relationship with short-term prognosis in colorectal cancer.

Annals of Saudi medicine

Erhan Y, Korkut MA, Kara E, Aydede H, Sakarya A, Ilkgü O.
PMID: 17146270
Ann Saudi Med. 2002 Sep-Nov;22(5):377-80. doi: 10.5144/0256-4947.2002.377.

No abstract available.

Cite
Erhan Y, Korkut MA, Kara E, et al. Value of p53 protein expression and its relationship with short-term prognosis in colorectal cancer. Ann Saudi Med. 2002;22(5):377-80doi: 10.5144/0256-4947.2002.377.
Erhan, Y., Korkut, M. A., Kara, E., Aydede, H., Sakarya, A., & Ilkgü, O. (2002). Value of p53 protein expression and its relationship with short-term prognosis in colorectal cancer. Annals of Saudi medicine, 22(5), 377-80. https://doi.org/10.5144/0256-4947.2002.377
Erhan, Yamaç, et al. "Value of p53 protein expression and its relationship with short-term prognosis in colorectal cancer." Annals of Saudi medicine vol. 22,5 (2002): 377-80. doi: https://doi.org/10.5144/0256-4947.2002.377
Erhan Y, Korkut MA, Kara E, Aydede H, Sakarya A, Ilkgü O. Value of p53 protein expression and its relationship with short-term prognosis in colorectal cancer. Ann Saudi Med. 2002 Sep-Nov;22(5):377-80. doi: 10.5144/0256-4947.2002.377. PMID: 17146270.
Copy Download .nbib Format: NLM
Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient.

International journal of nephrology and renovascular disease

Turkmen K, Altintepe L, Guney I, Aydogdu I, Koc O, Erkut MA, Tonbul HZ.
PMID: 21694931
Int J Nephrol Renovasc Dis. 2010;3:65-8. doi: 10.2147/ijnrd.s11077. Epub 2010 Jun 04.

Leukemic infiltration of the kidney is usually silent, and the admission of the patients with renal dysfunction or acute kidney injury is uncommon. We present a 34-year old hemodialysis patient with new onset of uncontrolled hypertension, erythropoietin-resistant anemia, thrombocytopenia,...

Cite
Turkmen K, Altintepe L, Guney I, et al. Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient. Int J Nephrol Renovasc Dis. 2010;3:65-8doi: 10.2147/ijnrd.s11077.
Turkmen, K., Altintepe, L., Guney, I., Aydogdu, I., Koc, O., Erkut, M. A., & Tonbul, H. Z. (2010). Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient. International journal of nephrology and renovascular disease, 365-8. https://doi.org/10.2147/ijnrd.s11077
Turkmen, Kultigin, et al. "Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient." International journal of nephrology and renovascular disease vol. 3 (2010): 65-8. doi: https://doi.org/10.2147/ijnrd.s11077
Turkmen K, Altintepe L, Guney I, Aydogdu I, Koc O, Erkut MA, Tonbul HZ. Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient. Int J Nephrol Renovasc Dis. 2010;3:65-8. doi: 10.2147/ijnrd.s11077. Epub 2010 Jun 04. PMID: 21694931; PMCID: PMC3108775.
Copy Download .nbib Format: NLM
Mesenteric fibromatosis of the ileocolic area: a case report.

The Indian journal of surgery

Caliskan C, Korkut MA.
PMID: 22468067
Indian J Surg. 2011 Apr;73(2):149-51. doi: 10.1007/s12262-010-0202-5. Epub 2010 Nov 16.

Fibromatosis is a kind of spindle cell tumor which is characterized by the remarkable proliferation and invasive growth of fibrous tissue. It often arises from the abdominal wall or the extremities and rarely from the mesentery and abdominal organs....

Cite
Caliskan C, Korkut MA. Mesenteric fibromatosis of the ileocolic area: a case report. Indian J Surg. 2010;73(2):149-51doi: 10.1007/s12262-010-0202-5.
Caliskan, C., & Korkut, M. A. (2011). Mesenteric fibromatosis of the ileocolic area: a case report. The Indian journal of surgery, 73(2), 149-51. https://doi.org/10.1007/s12262-010-0202-5
Caliskan, Cemil, and Korkut, Mustafa A. "Mesenteric fibromatosis of the ileocolic area: a case report." The Indian journal of surgery vol. 73,2 (2011): 149-51. doi: https://doi.org/10.1007/s12262-010-0202-5
Caliskan C, Korkut MA. Mesenteric fibromatosis of the ileocolic area: a case report. Indian J Surg. 2011 Apr;73(2):149-51. doi: 10.1007/s12262-010-0202-5. Epub 2010 Nov 16. PMID: 22468067; PMCID: PMC3077151.
Copy Download .nbib Format: NLM
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Zhao M, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz Pico CX, Demirhan M, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S, Meric-Bernstam F.
PMID: 33414137
Clin Cancer Res. 2021 Mar 15;27(6):1681-1694. doi: 10.1158/1078-0432.CCR-20-3017. Epub 2021 Jan 07.

PURPOSE: Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA approved for HER2-overexpressing/amplified (HER2EXPERIMENTAL DESIGN: Cell viability, colony formation assays, and Western blotting were used to determine the effect of neratinib RESULTS: In HER2CONCLUSIONS: Taken together, our...

Cite
Zhao M, Scott S, Evans KW, et al. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clin Cancer Res. 2021;27(6):1681-1694doi: 10.1158/1078-0432.CCR-20-3017.
Zhao, M., Scott, S., Evans, K. W., Yuca, E., Saridogan, T., Zheng, X., Wang, H., Korkut, A., Cruz Pico, C. X., Demirhan, M., Kirby, B., Kopetz, S., Diala, I., Lalani, A. S., Piha-Paul, S., & Meric-Bernstam, F. (2021). Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1681-1694. https://doi.org/10.1158/1078-0432.CCR-20-3017
Zhao, Ming, et al. "Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,6 (2021): 1681-1694. doi: https://doi.org/10.1158/1078-0432.CCR-20-3017
Zhao M, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz Pico CX, Demirhan M, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S, Meric-Bernstam F. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clin Cancer Res. 2021 Mar 15;27(6):1681-1694. doi: 10.1158/1078-0432.CCR-20-3017. Epub 2021 Jan 07. PMID: 33414137; PMCID: PMC8075007.
Copy Download .nbib Format: NLM
Synovial Sarcoma Mimicking Myositis Ossificans.

Knee surgery & related research

Balik MS, Erkut A, Guvercin Y, Bedir R.
PMID: 27595081
Knee Surg Relat Res. 2016 Sep;28(3):249-52. doi: 10.5792/ksrr.2016.28.3.249. Epub 2016 Aug 25.

A calcification mass was incidentally found in the soft tissue of a patient who had a history of trauma to the extremity during examination. The patient had no symptom. The pathological analysis of the mass revealed it was an...

Cite
Balik MS, Erkut A, Guvercin Y, et al. Synovial Sarcoma Mimicking Myositis Ossificans. Knee Surg Relat Res. 2016;28(3):249-52doi: 10.5792/ksrr.2016.28.3.249.
Balik, M. S., Erkut, A., Guvercin, Y., & Bedir, R. (2016). Synovial Sarcoma Mimicking Myositis Ossificans. Knee surgery & related research, 28(3), 249-52. https://doi.org/10.5792/ksrr.2016.28.3.249
Balik, Mehmet Sabri, et al. "Synovial Sarcoma Mimicking Myositis Ossificans." Knee surgery & related research vol. 28,3 (2016): 249-52. doi: https://doi.org/10.5792/ksrr.2016.28.3.249
Balik MS, Erkut A, Guvercin Y, Bedir R. Synovial Sarcoma Mimicking Myositis Ossificans. Knee Surg Relat Res. 2016 Sep;28(3):249-52. doi: 10.5792/ksrr.2016.28.3.249. Epub 2016 Aug 25. PMID: 27595081; PMCID: PMC5009052.
Copy Download .nbib Format: NLM
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.

Hepatology (Baltimore, Md.)

Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN.
PMID: 34510503
Hepatology. 2021 Sep 12; doi: 10.1002/hep.32150. Epub 2021 Sep 12.

BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is a deadly and highly therapy-refractory cancer of the bile ducts, with early results from immune checkpoint blockade trials showing limited responses. Whereas recent molecular assessments have made bulk characterizations of immune profiles and...

Cite
Carapeto F, Bozorgui B, Shroff RT, et al. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2021;doi: 10.1002/hep.32150.
Carapeto, F., Bozorgui, B., Shroff, R. T., Chagani, S., Solis Soto, L., Foo, W. C., Wistuba, I., Meric-Bernstam, F., Shalaby, A., Javle, M., Korkut, A., & Kwong, L. N. (2021). The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology (Baltimore, Md.), . https://doi.org/10.1002/hep.32150
Carapeto, Fernando, et al. "The immunogenomic landscape of resected intrahepatic cholangiocarcinoma." Hepatology (Baltimore, Md.) vol. (2021). doi: https://doi.org/10.1002/hep.32150
Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2021 Sep 12; doi: 10.1002/hep.32150. Epub 2021 Sep 12. PMID: 34510503.
Copy Download .nbib Format: NLM
Quadriceps Tendon Rupture due to Postepileptic Convulsion.

Knee surgery & related research

Balik MS, Erkut A, Guvercin Y, Sahin R, Keskin D.
PMID: 24944977
Knee Surg Relat Res. 2014 Jun;26(2):114-6. doi: 10.5792/ksrr.2014.26.2.114. Epub 2014 May 30.

We present a case of quadriceps tendon (QT) rupture. QT ruptures can occur in all ages. The cause is mostly traumatic in origin. Spontaneous ruptures that are thought to result from predisposing conditions are rare. Post-convulsion QT ruptures lacking...

Cite
Balik MS, Erkut A, Guvercin Y, et al. Quadriceps Tendon Rupture due to Postepileptic Convulsion. Knee Surg Relat Res. 2014;26(2):114-6doi: 10.5792/ksrr.2014.26.2.114.
Balik, M. S., Erkut, A., Guvercin, Y., Sahin, R., & Keskin, D. (2014). Quadriceps Tendon Rupture due to Postepileptic Convulsion. Knee surgery & related research, 26(2), 114-6. https://doi.org/10.5792/ksrr.2014.26.2.114
Balik, Mehmet Sabri, et al. "Quadriceps Tendon Rupture due to Postepileptic Convulsion." Knee surgery & related research vol. 26,2 (2014): 114-6. doi: https://doi.org/10.5792/ksrr.2014.26.2.114
Balik MS, Erkut A, Guvercin Y, Sahin R, Keskin D. Quadriceps Tendon Rupture due to Postepileptic Convulsion. Knee Surg Relat Res. 2014 Jun;26(2):114-6. doi: 10.5792/ksrr.2014.26.2.114. Epub 2014 May 30. PMID: 24944977; PMCID: PMC4061405.
Copy Download .nbib Format: NLM
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.

Hepatology (Baltimore, Md.)

Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN.
PMID: 34510503
Hepatology. 2022 Feb;75(2):297-308. doi: 10.1002/hep.32150. Epub 2021 Dec 06.

BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is a deadly and highly therapy-refractory cancer of the bile ducts, with early results from immune checkpoint blockade trials showing limited responses. Whereas recent molecular assessments have made bulk characterizations of immune profiles and...

Cite
Carapeto F, Bozorgui B, Shroff RT, et al. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2021;75(2):297-308doi: 10.1002/hep.32150.
Carapeto, F., Bozorgui, B., Shroff, R. T., Chagani, S., Solis Soto, L., Foo, W. C., Wistuba, I., Meric-Bernstam, F., Shalaby, A., Javle, M., Korkut, A., & Kwong, L. N. (2022). The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology (Baltimore, Md.), 75(2), 297-308. https://doi.org/10.1002/hep.32150
Carapeto, Fernando, et al. "The immunogenomic landscape of resected intrahepatic cholangiocarcinoma." Hepatology (Baltimore, Md.) vol. 75,2 (2022): 297-308. doi: https://doi.org/10.1002/hep.32150
Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 Feb;75(2):297-308. doi: 10.1002/hep.32150. Epub 2021 Dec 06. PMID: 34510503.
Copy Download .nbib Format: NLM
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Akcakanat A, Zheng X, Cruz Pico CX, Kim TB, Chen K, Korkut A, Sahin A, Holla V, Tarco E, Singh G, Damodaran S, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.
PMID: 33782032
Clin Cancer Res. 2021 Jun 01;27(11):3243-3252. doi: 10.1158/1078-0432.CCR-20-4048. Epub 2021 Mar 29.

PURPOSE: Metastatic breast cancer (MBC) is not curable and there is a growing interest in personalized therapy options. Here we report molecular profiling of MBC focusing on molecular evolution in actionable alterations.EXPERIMENTAL DESIGN: Sixty-two patients with MBC were included....

Cite
Akcakanat A, Zheng X, Cruz Pico CX, et al. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res. 2021;27(11):3243-3252doi: 10.1158/1078-0432.CCR-20-4048.
Akcakanat, A., Zheng, X., Cruz Pico, C. X., Kim, T. B., Chen, K., Korkut, A., Sahin, A., Holla, V., Tarco, E., Singh, G., Damodaran, S., Mills, G. B., Gonzalez-Angulo, A. M., & Meric-Bernstam, F. (2021). Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(11), 3243-3252. https://doi.org/10.1158/1078-0432.CCR-20-4048
Akcakanat, Argun, et al. "Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,11 (2021): 3243-3252. doi: https://doi.org/10.1158/1078-0432.CCR-20-4048
Akcakanat A, Zheng X, Cruz Pico CX, Kim TB, Chen K, Korkut A, Sahin A, Holla V, Tarco E, Singh G, Damodaran S, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res. 2021 Jun 01;27(11):3243-3252. doi: 10.1158/1078-0432.CCR-20-4048. Epub 2021 Mar 29. PMID: 33782032; PMCID: PMC8172429.
Copy Download .nbib Format: NLM
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.

Hepatology (Baltimore, Md.)

Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN.
PMID: 34510503
Hepatology. 2021 Sep 12; doi: 10.1002/hep.32150. Epub 2021 Sep 12.

BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is a deadly and highly therapy-refractory cancer of the bile ducts, with early results from immune checkpoint blockade trials showing limited responses. Whereas recent molecular assessments have made bulk characterizations of immune profiles and...

Cite
Carapeto F, Bozorgui B, Shroff RT, et al. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2021;doi: 10.1002/hep.32150.
Carapeto, F., Bozorgui, B., Shroff, R. T., Chagani, S., Solis Soto, L., Foo, W. C., Wistuba, I., Meric-Bernstam, F., Shalaby, A., Javle, M., Korkut, A., & Kwong, L. N. (2021). The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology (Baltimore, Md.), . https://doi.org/10.1002/hep.32150
Carapeto, Fernando, et al. "The immunogenomic landscape of resected intrahepatic cholangiocarcinoma." Hepatology (Baltimore, Md.) vol. (2021). doi: https://doi.org/10.1002/hep.32150
Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2021 Sep 12; doi: 10.1002/hep.32150. Epub 2021 Sep 12. PMID: 34510503.
Copy Download .nbib Format: NLM
Analyzing causal relationships in proteomic profiles using CausalPath.

STAR protocols

Luna A, Siper MC, Korkut A, Durupinar F, Dogrusoz U, Aslan JE, Sander C, Demir E, Babur O.
PMID: 34877547
STAR Protoc. 2021 Nov 23;2(4):100955. doi: 10.1016/j.xpro.2021.100955. eCollection 2021 Dec 17.

CausalPath (causalpath.org) evaluates proteomic measurements against prior knowledge of biological pathways and infers causality between changes in measured features, such as global protein and phospho-protein levels. It uses pathway resources to determine potential causality between observable omic features, which...

Cite
Luna A, Siper MC, Korkut A, et al. Analyzing causal relationships in proteomic profiles using CausalPath. STAR Protoc. 2021;2(4):100955doi: 10.1016/j.xpro.2021.100955.
Luna, A., Siper, M. C., Korkut, A., Durupinar, F., Dogrusoz, U., Aslan, J. E., Sander, C., Demir, E., & Babur, O. (2021). Analyzing causal relationships in proteomic profiles using CausalPath. STAR protocols, 2(4), 100955. https://doi.org/10.1016/j.xpro.2021.100955
Luna, Augustin, et al. "Analyzing causal relationships in proteomic profiles using CausalPath." STAR protocols vol. 2,4 (2021): 100955. doi: https://doi.org/10.1016/j.xpro.2021.100955
Luna A, Siper MC, Korkut A, Durupinar F, Dogrusoz U, Aslan JE, Sander C, Demir E, Babur O. Analyzing causal relationships in proteomic profiles using CausalPath. STAR Protoc. 2021 Nov 23;2(4):100955. doi: 10.1016/j.xpro.2021.100955. eCollection 2021 Dec 17. PMID: 34877547; PMCID: PMC8633371.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 27 entries